Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]
In development
Reference number: GID-TA11477
Expected publication date: TBC
The appraisal has been delayed following a request from the company.
This evaluation will now go ahead as a Single Technology Appraisal (STA). This evaluation will only cover semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis.
The evaluation will begin in early November 2025.